These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 314526)

  • 1. [Immune responses to fusion of normal cells and those of tumor-bearing mice].
    Tachibana T
    Nihon Hifuka Gakkai Zasshi; 1978 Nov; 88(12):797-802. PubMed ID: 314526
    [No Abstract]   [Full Text] [Related]  

  • 2. Tumor regression in tumor-bearing mice by inoculations of immunogenic somatic hybrid cells in combination with cyclophosphamide.
    Tachibana T; Dei T
    Tokai J Exp Clin Med; 1983 Dec; 8(5-6):455-63. PubMed ID: 6681341
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activation of specific cellular immunity toward murine leukemia in mice rejecting syngeneic somatic hybrid cells.
    Liang W; Cohen EP
    J Immunol; 1977 Sep; 119(3):1054-60. PubMed ID: 302270
    [No Abstract]   [Full Text] [Related]  

  • 4. [Induction of Th1 immune response against tumor by genetically engineered fusion of tumor cells and dendritic cells].
    Zhang W; Yang H; Zeng H; Chen Z
    Zhonghua Xue Ye Xue Za Zhi; 2002 Feb; 23(2):61-4. PubMed ID: 12015071
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor-specific immunity induced by somatic hybrids. II. Elicitation of enhanced immunity against the parent plasmacytoma.
    Kim BS
    J Immunol; 1979 Aug; 123(2):739-44. PubMed ID: 88483
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of cell-mediated antiviral immunity and macrophage activation in C3H/HeN mice infected with mouse mammary tumor virus.
    Tagliabue A; Boraschi D; McCoy JL
    J Immunol; 1980 May; 124(5):2203-8. PubMed ID: 6245137
    [No Abstract]   [Full Text] [Related]  

  • 7. Normal tissue alloantigens and genetic control of susceptibility to tumors: microcytotoxicity studies on resistant C3Hf and susceptible (A X C3Hf) F1 mice inoculated with transplacentally induced C3Hf lung tumor.
    Martin WJ; Esber E; Cotton WG; Rice JM
    J Immunol; 1975 Jul; 115(1):289-295. PubMed ID: 50354
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Native anti-tumor responses elicited by immunization with a low dose of unmodified live tumor cells.
    Wu S; Wang SQ; Zhang J; Tan XY; Liu JN
    Int J Oncol; 2006 Mar; 28(3):731-6. PubMed ID: 16465379
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Studies on macrophage-activating factor (MAF) in antitumor immune responses. I. Tumor-specific Lyt-1+2- T cells are required for producing MAF able to generate cytolytic as well as cytostatic macrophages.
    Nakajima H; Fujiwara H; Takai Y; Izumi Y; Sano S; Tsuchida T; Hamaoka T
    J Immunol; 1985 Sep; 135(3):2199-205. PubMed ID: 3894520
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Functional cytotoxic T lymphocyte hybridomas.
    Kaufmann Y; Berke G; Eshhar Z
    Transplant Proc; 1981 Mar; 13(1 Pt 2):1170-4. PubMed ID: 6973859
    [No Abstract]   [Full Text] [Related]  

  • 11. Relevance of spontaneous in vivo tumor-host cell fusion to tumor progression and metastasis evaluated using a series of lectin-resistant mutant tumor sublines.
    Kerbel RS; Lagarde AE; Dennis JW; Nestel FP; Donaghue TP; Siminovitch L; Fulchignoni-Lataud MC
    Symp Fundam Cancer Res; 1983; 36():47-79. PubMed ID: 6382520
    [No Abstract]   [Full Text] [Related]  

  • 12. Dominance of resistance to the cytocidal effect of tumor necrosis factor in heterokaryons formed by fusion of resistant and sensitive cells.
    Nophar Y; Holtmann H; Ber R; Wallach D
    J Immunol; 1988 May; 140(10):3456-60. PubMed ID: 2834438
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Halothane-induced suppression of cell-mediated immunity in normal and tumor-bearing C3Hf/He mice.
    Lewis RE; Cruse JM; Hazelwood J
    Anesth Analg; 1980 Sep; 59(9):666-71. PubMed ID: 7191225
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Significance of suppressor macrophages for immunosurveillance of tumor-bearing mice.
    Fujii T; Igarashi T; Kishimoto S
    J Natl Cancer Inst; 1987 Mar; 78(3):509-17. PubMed ID: 2950265
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Eliciting T cell immunity against poorly immunogenic tumors by immunization with dendritic cell-tumor fusion vaccines.
    Wang J; Saffold S; Cao X; Krauss J; Chen W
    J Immunol; 1998 Nov; 161(10):5516-24. PubMed ID: 9820528
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cellular cytotoxicity and serum inhibition in normal mice following transfer of syngeneic tumor-sensitized cells.
    Fisher B; Wolmark N; Saffer EA
    J Natl Cancer Inst; 1980 Mar; 64(3):579-85. PubMed ID: 6986497
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytostatic effect of spleen cells of tumor-bearing mice on syngenetic tumor cells.
    Lespinats G; Poupon MF
    Cancer Res; 1977 Jun; 37(6):1727-32. PubMed ID: 870185
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunoglobulin gene rearrangements in hybridoma cells.
    Wilson R; Storb U; Arp B
    J Immunol; 1980 May; 124(5):2071-6. PubMed ID: 6245134
    [No Abstract]   [Full Text] [Related]  

  • 19. [Host's immune responses against tumor].
    Fujiwara H
    Rinsho Byori; 1989 Jul; (Spec No 82):35-41. PubMed ID: 2614962
    [No Abstract]   [Full Text] [Related]  

  • 20. Comparative in vitro studies on effector cell diversity in the cellular immune response to murine sarcoma virus (MSV)-induced tumors in mice.
    Plata F; Gomard E; Leclerc JC; Levy JP
    J Immunol; 1974 Apr; 112(4):1477-87. PubMed ID: 4360862
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.